Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 10 Best US Stocks Under $5 to Buy. On May 6, Canaccord reiterated its Buy rating on Taysha Gene Therapies, Inc. (NASDAQ:TSHA) with a price target of $17 on the stock.

This update comes after the company reported results for the first quarter of 2026. Taysha Gene Therapies, Inc. (NASDAQ:TSHA) said it recently held an initial breakthrough therapy Type B multidisciplinary meeting with the US Food and Drug Administration (FDA).

Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights

Following the meeting, the company confirmed that it remains aligned with the planned path toward a Biologics License Application (BLA) submission for TSHA-102. This includes the pivotal trial design, study endpoints, and possible BLA submission scenarios. One of those scenarios could allow the company to seek approval based on the six-month interim analysis from the REVEAL pivotal trial.

Additionally, Taysha Gene Therapies, Inc. (NASDAQ:TSHA) reported that enrollment is continuing in the ASPIRE trial across multiple clinical trial sites. The ASPIRE safety-focused trial is intended to support a future BLA submission that could allow broader labeling of TSHA-102 for patients aged two years and older with Rett syndrome.

The company expects dosing in both the REVEAL pivotal trial and the ASPIRE trial to be completed in the second quarter of 2026.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company. It focuses on developing adeno-associated virus (AAV)-based gene therapies to treat serious monogenic diseases of the central nervous system.

While we acknowledge the risk and potential of TSHA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TSHA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Mid-Cap Stocks That Are On Fire Right Now and 10 Best American Tech Stocks to Buy.

Disclosure: None.  Follow Insider Monkey on Google News.